Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rohto Pharmaceutical Co ( (JP:4527) ) just unveiled an announcement.
Rohto Pharmaceutical Co., Ltd. has announced the terms for its issuance of Zero Coupon Convertible Bonds due 2032, following a board resolution on February 26, 2025. The bonds, which include stock acquisition rights, are part of the company’s strategic financial initiatives. The conversion price is set at ¥2,828.5, with a conversion premium of 23.01% over the closing share price on the Tokyo Stock Exchange. This move is expected to enhance Rohto’s financial flexibility and potentially strengthen its market position by allowing for future stock acquisition.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing primarily on the development and sale of health and wellness products. The company is known for its range of over-the-counter medications, skincare products, and other health-related goods, with a strong market presence in Japan and expanding operations globally.
YTD Price Performance: -14.08%
Average Trading Volume: 5,490
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.55B
See more insights into 4527 stock on TipRanks’ Stock Analysis page.